BeyondSpring is trading at $0.77, down 31.22% at 9:32 a.m. Eastern on September 29; available evidence does not establish a cause for the decline. - It closed at $1.12 on September 28. - BeyondSpring announced FDA Fast Track designation for plinabulin and a China subsidiary transaction to help fund its Phase 3 DUBLIN-4 trial. - Major indices were mixed in the provided market snapshot, with no broad same-direction decline clearly accounting for the move.